| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Peter Hjorth, Sebastian Markvard Petersen, Tine Louise Launholt, Connie Thurøe Nielse. Effect of apple vinegar intake on metabolic parameters and constipation in patients with schizophrenia treated with clozapine: a pilot study. Nordic journal of psychiatry. vol 75. issue 2. 2021-02-03. PMID:32762505. |
effect of apple vinegar intake on metabolic parameters and constipation in patients with schizophrenia treated with clozapine: a pilot study. |
2021-02-03 |
2023-08-13 |
Not clear |
| Meha Verma, Sandeep Grover, Subho Chakrabart. Effect of clozapine on psychological outcomes of caregivers of patients with treatment resistant schizophrenia. Nordic journal of psychiatry. vol 75. issue 2. 2021-02-03. PMID:32820680. |
effect of clozapine on psychological outcomes of caregivers of patients with treatment resistant schizophrenia. |
2021-02-03 |
2023-08-13 |
Not clear |
| Meha Verma, Sandeep Grover, Subho Chakrabart. Effectiveness of clozapine on quality of life and functioning in patients with treatment-resistant schizophrenia. Nordic journal of psychiatry. vol 75. issue 2. 2021-02-03. PMID:32915089. |
effectiveness of clozapine on quality of life and functioning in patients with treatment-resistant schizophrenia. |
2021-02-03 |
2023-08-13 |
Not clear |
| Meha Verma, Sandeep Grover, Subho Chakrabart. Effectiveness of clozapine on quality of life and functioning in patients with treatment-resistant schizophrenia. Nordic journal of psychiatry. vol 75. issue 2. 2021-02-03. PMID:32915089. |
accordingly, this study aimed to evaluate the short term (3 months) effectiveness of clozapine in patients with treatment-resistant schizophrenia (trs) in terms of quality of life, disability, and level of functioning. |
2021-02-03 |
2023-08-13 |
Not clear |
| Mary V Seema. The Gut Microbiome and Treatment-Resistance in Schizophrenia. The Psychiatric quarterly. vol 91. issue 1. 2021-02-01. PMID:31781943. |
the effect of antipsychotic medication is poor in 30-40% of patients with schizophrenia; treatment resistance is usually met with shifts to new drugs or drug augmentation strategies or a trial of clozapine. |
2021-02-01 |
2023-08-13 |
Not clear |
| V Chow, T Yeoh, A C C Ng, T Pasqualon, E Scott, J Plater, B Whitwell, D Hanzek, T Chung, L Thomas, D S Celermajer, L Kritharide. Asymptomatic left ventricular dysfunction with long-term clozapine treatment for schizophrenia: a multicentre cross-sectional cohort study. Open heart. vol 1. issue 1. 2021-01-29. PMID:25332789. |
asymptomatic left ventricular dysfunction with long-term clozapine treatment for schizophrenia: a multicentre cross-sectional cohort study. |
2021-01-29 |
2023-08-13 |
Not clear |
| V Chow, T Yeoh, A C C Ng, T Pasqualon, E Scott, J Plater, B Whitwell, D Hanzek, T Chung, L Thomas, D S Celermajer, L Kritharide. Asymptomatic left ventricular dysfunction with long-term clozapine treatment for schizophrenia: a multicentre cross-sectional cohort study. Open heart. vol 1. issue 1. 2021-01-29. PMID:25332789. |
patients with schizophrenia treated with clozapine are at risk of acute myocarditis and dilated cardiomyopathy. |
2021-01-29 |
2023-08-13 |
Not clear |
| Özcan Uzun, Abdullah Bolu, Cemil Çeli. Effect of N-acetylcysteine on clozapine-induced sialorrhea in schizophrenic patients: a case series. International clinical psychopharmacology. vol 35. issue 4. 2021-01-29. PMID:31743234. |
clozapine is an atypical antipsychotic demonstrated to be superior in the treatment of refractory schizophrenia. |
2021-01-29 |
2023-08-13 |
Not clear |
| Amir Krivoy, Joshua Satz, Shay H Hornfeld, Lior Bar, Fiona Gaughran, Gal Shoval, Eldar Hochman, Abraham Weizman, Michal Tale. Low levels of serum vitamin D in clozapine-treated schizophrenia patients are associated with high levels of the proinflammatory cytokine IL-6. International clinical psychopharmacology. vol 35. issue 4. 2021-01-29. PMID:31913874. |
this relationship may indicate an immunomodulatory effect of vitamin d in treatment-resistant patients with schizophrenia maintained on clozapine. |
2021-01-29 |
2023-08-13 |
human |
| Masaru Nakamura, Takahiko Nagamin. Eosinophilic pneumonia during treatment with clozapine: reports from a retrospective case series. International clinical psychopharmacology. vol 35. issue 5. 2021-01-29. PMID:32282447. |
the aim of this study was to investigate the relationship between clozapine usage and drug-induced pneumonia based on characteristic respiratory symptoms and radiological findings, retrospectively in 69 japanese treatment-resistant schizophrenia patients. |
2021-01-29 |
2023-08-13 |
human |
| Julia E H Brow. Relegating Psychosis: Blood Work and "Routine Connection" in the Clozapine Clinic. Culture, medicine and psychiatry. vol 44. issue 2. 2021-01-25. PMID:31598807. |
the clozapine clinic is where people diagnosed with chronic schizophrenia who take the antipsychotic clozapine go for routine monitoring of clozapine side effects, particularly haematological effects. |
2021-01-25 |
2023-08-13 |
Not clear |
| Julia E H Brow. Relegating Psychosis: Blood Work and "Routine Connection" in the Clozapine Clinic. Culture, medicine and psychiatry. vol 44. issue 2. 2021-01-25. PMID:31598807. |
the importance of unemotional but unfailing relationships and rhythms in the clozapine clinic context echoes cross-cultural findings about how schizophrenia is managed more productively in environments that invite more neutral and equal social exchanges. |
2021-01-25 |
2023-08-13 |
Not clear |
| Takahiro Masuda, Fuminari Misawa, Masayuki Takase, John M Kane, Christoph U Correl. Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta-analysis of Cohort Studies. JAMA psychiatry. vol 76. issue 10. 2021-01-21. PMID:31365048. |
association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics: a systematic review and meta-analysis of cohort studies. |
2021-01-21 |
2023-08-13 |
Not clear |
| Takahiro Masuda, Fuminari Misawa, Masayuki Takase, John M Kane, Christoph U Correl. Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta-analysis of Cohort Studies. JAMA psychiatry. vol 76. issue 10. 2021-01-21. PMID:31365048. |
recent meta-analyses of randomized clinical trials (rcts) comparing clozapine with nonclozapine second-generation antipsychotics (nc-sgas) in schizophrenia have challenged clozapine's superiority in treatment-resistant patients. |
2021-01-21 |
2023-08-13 |
Not clear |
| Hein Bokern, Niels Jonker, Dan Cohe. Creatine kinase elevation and discontinuation of clozapine: fear-driven clinical practice in a forensic case with treatment-resistant schizophrenia and persistent violent behaviour. BJPsych open. vol 7. issue 1. 2021-01-16. PMID:33272348. |
creatine kinase elevation and discontinuation of clozapine: fear-driven clinical practice in a forensic case with treatment-resistant schizophrenia and persistent violent behaviour. |
2021-01-16 |
2023-08-13 |
Not clear |
| Hein Bokern, Niels Jonker, Dan Cohe. Creatine kinase elevation and discontinuation of clozapine: fear-driven clinical practice in a forensic case with treatment-resistant schizophrenia and persistent violent behaviour. BJPsych open. vol 7. issue 1. 2021-01-16. PMID:33272348. |
in forensic settings, the most common indication for clozapine is treatment-resistant schizophrenia (trs). |
2021-01-16 |
2023-08-13 |
Not clear |
| Hein Bokern, Niels Jonker, Dan Cohe. Creatine kinase elevation and discontinuation of clozapine: fear-driven clinical practice in a forensic case with treatment-resistant schizophrenia and persistent violent behaviour. BJPsych open. vol 7. issue 1. 2021-01-16. PMID:33272348. |
clozapine has also been shown to be effective in reducing hostility, aggression and violence in patients with schizophrenia and is of benefit in comorbid substance use disorders. |
2021-01-16 |
2023-08-13 |
Not clear |
| Juan Andrés Martínez-Andrés, Juan Antonio García-Carmon. Switching from clozapine to paliperidone palmitate-3-monthly improved obesity, hyperglycemia and dyslipidemia lowering antipsychotic dose equivalents in a treatment-resistant schizophrenia cohort. International clinical psychopharmacology. vol 35. issue 3. 2021-01-13. PMID:31851035. |
switching from clozapine to paliperidone palmitate-3-monthly improved obesity, hyperglycemia and dyslipidemia lowering antipsychotic dose equivalents in a treatment-resistant schizophrenia cohort. |
2021-01-13 |
2023-08-13 |
Not clear |
| Juan Andrés Martínez-Andrés, Juan Antonio García-Carmon. Switching from clozapine to paliperidone palmitate-3-monthly improved obesity, hyperglycemia and dyslipidemia lowering antipsychotic dose equivalents in a treatment-resistant schizophrenia cohort. International clinical psychopharmacology. vol 35. issue 3. 2021-01-13. PMID:31851035. |
clozapine, an antipsychotic developed in 1958, is considered the gold standard and the treatment of choice in treatment-resistant schizophrenia despite its side effects and despite 40-70% of these patients not responding to clozapine. |
2021-01-13 |
2023-08-13 |
Not clear |
| Juan Andrés Martínez-Andrés, Juan Antonio García-Carmon. Switching from clozapine to paliperidone palmitate-3-monthly improved obesity, hyperglycemia and dyslipidemia lowering antipsychotic dose equivalents in a treatment-resistant schizophrenia cohort. International clinical psychopharmacology. vol 35. issue 3. 2021-01-13. PMID:31851035. |
the aim of our study was to carry out an exploratory evaluation of endocrine and hepatic profiles as well as the concomitant treatments associated to pp3m vs. clozapine, the gold standard, in patients with treatment-resistant schizophrenia. |
2021-01-13 |
2023-08-13 |
Not clear |